New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Volume 2, # 1 - May, 1996

Table of Contents

STATE-OF-THE-ART MANAGEMENT OF CANCER
PROSTATE CANCER - PART I
Epidemiology 282
Prostate Anatomy, Histology and Cancer Pathology 284
Etiology and Pathogenesis 284
  Genetic Factors 284
  Growth Factors 286
Screening and Chemoprevention 287
  Screening Using PSA 287
  Chemoprevention 288
Diagnosis 288
  Prostate Specific Antigen (PSA) 288
  Other Biomarkers 289
    AntiCancer 289
    Cytogen 289
    DIANON Systems 289
    Horus Therapeutics 290
    Matritech 290
    Oncor 290
  Biopsy 290
  Radionuclide Bone Scans 291
  Radioimmunoscintigraphy 291
  Other Diagnostic Tests 291
    Optical Imaging 291
Staging 291
Prognosis 291
Treatment of Prostate Cancer 292
  Treatment of Localized Prostate Cancer 292
    Radical prostatectomy 293
    Neoadjuvant hormonal ablation therapy 293
    External beam radiation therapy 295
    Brachytherapy 295
    Cryotherapy 295
    Hyperthermia 296
    Photodynamic therapy 296
    Fast neutron therapy 297
    Boron neutron capture therapy 297
MEETING COVERAGE
ADVANCES IN THE TREATMENT OF PROSTATE CANCER
From the 32nd Annual Meeting of the American Society of Clinical Oncology
Philadelphia, PA - May 18-21, 1996
PSA Level as Predictor of Survival Following Prostate Cancer Radiation Therapy 298
Combined Modality Therapy In Locally-Advanced Disease 298
Anti-androgens in Previously Untreated Metastatic Prostate Cancer 298
Potency Sparing Therapy for Advanced Disease 299
Treatment of Hormone Refractory Prostate Cancer 299

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887